FDA approves FlexAbility Ablation Catheter, Sensor Enabled to treat atrial flutter,-Abbott
Abbott has announced FDA approval of the FlexAbility Ablation Catheter, Sensor Enabled designed to improve the versatility and precision during cardiac ablation procedures to treat atrial flutter, a type of irregular heartbeat. With the approval, the company has further expanded its electrophysiology portfolio for treating patients struggling with abnormal heart rhythms (cardiac arrhythmias).
The FlexAbility Ablation Catheter, Sensor Enabled is the first ablation catheter from Abbott that helps collect both electrical current resistance (impedance) and magnetic data to facilitate detailed, accurate mapping as well as assist in the treatment of sites that trigger or sustain abnormal heart rhythms.
Comment:FlexAbility Ablation Catheter, Sensor Enabled received CE Mark approval in July 2014 for St Jude Medical which is now a subsidiary of Abbott.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.